Original Report

Improving access with a collaborative approach to cancer genetic counseling services: a pilot study


 

Background Limited access to cancer genetic counselors (GC) may result in the lack of patient identification and/or failure to show due to travel distance and complicated treatment schedules.

Objective We hypothesized that access would improve when a GC collaborated with distant nongenetics health care providers to provide services locally.

Methods Patients at a collaborative site were offered a risk assessment survey that was reviewed remotely by a licensed, boardcertified GC. Patients were triaged such that the onsite registered nurse (RN) provided basic risk assessment and offered genetic testing for straight-forward hereditary breast and ovarian cases. Ongoing training and support was provided by the GC. Followup and complex cases were scheduled with the GC during a monthly outreach visit to the collaborative site.

Results During the 1-year study period, the total number of patients who accessed genetic counseling services from the target region was 4 times greater than the previous year. Ten of 17 patients who were triaged for genetic counseling and testing underwent genetic risk assessment services as a result of this identification and triage protocol.

Conclusion This defines a workable approach for patient identification and triage for hereditary cancer risk assessment and genetic counseling in a community setting. This collaborative approach may be applicable to centers that do not have access to a board-certified GC, especially important in light of the 2012 Commission on Cancer Standards that require cancer risk assessment, genetic counseling and testing services on site or by referral.

Click on the PDF icon at the top of this introduction to read the full article.

Recommended Reading

Best practices for pediatric palliative cancer care: a primer for clinical providers
MDedge Hematology and Oncology
Complementary and alternative medicine (CAM) use in advanced cancer: a systematic review
MDedge Hematology and Oncology
Chlorpromazine bioavailability from a topical gel formulation in volunteers
MDedge Hematology and Oncology
Gender differences in the evolution of illness understanding among patients with advanced cancer
MDedge Hematology and Oncology
Dalteparin safely used for 12 months to prevent VTE recurrence in cancer patients
MDedge Hematology and Oncology
Nail complications of cancer therapies on the rise
MDedge Hematology and Oncology
Guideline-recommended beta-blockers before noncardiac surgery shown to increase mortality by 27%
MDedge Hematology and Oncology
Building patient-centered care through values assessment integration with advance care planning
MDedge Hematology and Oncology
How can social media improve oncology care?
MDedge Hematology and Oncology
Reconciling patient access to care
MDedge Hematology and Oncology

Related Articles